Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

HER2 -vaksine for lokalt avansert brystkreft

3. november 2026 oppdatert av: Pravin T.P Kaumaya

Fase I-studie av en kimær (trastuzumab-lignende og pertuzumab-lignende) HER2 B-cellepeptidvaksine emulgerte i ISA 720 adjuvans for lokalt avansert HER2-positiv brystkreft

The goal of this study is to test an investigational vaccine to activate the immune system to fight breast cancer.

Studieoversikt

Status

Rekruttering

Intervensjon / Behandling

Studietype

Intervensjonell

Registrering (Antatt)

36

Fase

  • Fase 1

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

    • Indiana
      • Indianapolis, Indiana, Forente stater, 46202
        • Rekruttering
        • Indiana University Melvin & Bren Simon Comprehensive Cancer Center
        • Hovedetterforsker:
          • Pravin Kaumaya, PhD
        • Ta kontakt med:

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  1. ≥ 18 years old at the time of informed consent

  2. Ability to provide written informed consent and HIPAA authorization CTO-IUSCC-0864

  3. Histologically confirmed HER2 positive breast cancer

    1. Any Estrogen Receptor/Progesterone Receptor status is allowed.
    2. HER2 positive is defined as HER2 3+ by immunohistochemistry (IHC) or 2+ by IHC associated with a fluorescence in situ hybridization (FISH) ratio of > 2.0 or > 6 total HER2 gene copies per cell.
  4. High-risk disease defined as one of the following:

    1. Any residual invasive carcinoma in the breast or axillary nodes in the final pathology from resected tumor following neoadjuvant taxane and trastuzumab-based chemotherapy
    2. Inflammatory phenotype at the time of diagnosis per the treating physician
    3. Clinical stage III disease at the time of diagnosis per the treating physician and/or clinical imaging
    4. Locally recurrent disease and have undergone definitive local therapy
  5. Received at least six months of HER2 targeted therapy with trastuzmab +/- pertuzumab TDM-1, or others in the neoadjuvant or adjuvant setting

    a. Any combination of HER2 targeted therapy in the curative setting is allowed, including neratinib or others on a clinical trial

  6. Completed last dose of HER2 targeted therapy no more than 6 months prior to registration

  7. Completed last dose of cytotoxic chemotherapy or radiation at least 30 days prior to registration with resolution of any prior toxicity to ≤ 2 with the exception of alopecia

  8. ECOG performance status of 0 to 2

  9. Adequate organ function as indicated by:

    1. Total bilirubin < 1.5 mg/dL (except in patients with documented Gilbert's disease, who must have a total bilirubin < 3.0 mg/dL)
    2. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2.0 x ULN
    3. Calculated creatinine clearance of > 60 mL/min using the Cockcroft-Gault formula
    4. Absolute neutrophil count (ANC) > 1.0 K/mm3
    5. Platelets > 100 K/ mm3
  10. Adequate cardiac function defined as left ventricular ejection fraction (LVEF) above the institutional lower limit of normal by echocardiogram or MUGA obtained within 90 days of registration

  11. Women of childbearing potential must have a negative serum pregnancy test within 14 days of protocol registration. Women are considered to have childbearing potential (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) unless they meet one of the following criteria:

    1. Has undergone a hysterectomy or bilateral oophorectomy; or
    2. Has been naturally amenorrheic for at least 12 consecutive months.
  12. Women of childbearing potential and men must agree to use one effective contraception throughout the study and for 6 months after the last study treatment.

Note: Acceptable methods of birth control include abstinence, partner with previous vasectomy, placement of an intrauterine device (IUD), condom with spermicidal foam/gel/film/cream/suppository, diaphragm or cervical vault cap, or hormonal birth control (pills or injections).

Exclusion Criteria:

  1. Any distant disease recurrence.

  2. Patients with active malignancy other than breast cancer. Note: Patients with prior malignancies without recurrence after standard treatment will not be excluded.

  3. Patients receiving or planned to receive adjuvant CDK4/6 inhibitor therapy

  4. Patients who are {MVF-HER-2(266-296) and MVF-HER-2 (597-626)} immediate hypersensitivity skin test positive.

  5. Patients who require or likely to require corticosteroids or other immunosuppressives

  6. Patients with active autoimmune diseases including rheumatoid arthritis, systemic lupus erythematosus, scleroderma, polymyositis dermato-myositis, or a vasculitic syndrome.

    Note: At the discretion of the treating physician, patients who show disease control for at least 6 months and do not require immunosuppressives may be enrolled.

  7. Patients who have developed anaphylactic responses to other vaccines.

  8. Patients who have evidence of active infection that requires antibiotic therapy. Patients must have been off antibiotic treatment for at least 3 weeks prior to initiating treatment and must be confirmed to be clear of the infection.

  9. Known seropositive or active viral infection with human immunodeficiency virus (HIV), hepatitis B (HBV), or hepatitis C (HCV). Seropositivity due to vaccination are eligible.

  10. Uncontrolled illness that would limit safety or compliance with study procedures including, but not limited to, active infection, congestive heart failure, unstable angina, or cardiac arrhythmia.

  11. Patients with serious uncontrolled cardiopulmonary disorders, including congestive heart failure, symptomatic coronary artery disease, serious cardiac arrhythmia, and symptomatic chronic obstructive pulmonary disease or patients with other serious uncontrolled medical diseases. At the discretion of the treating physician, patients who show disease control for at least 6 months may be enrolled.

  12. History of splenectomy

  13. Pregnant or breast feeding.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: N/A
  • Intervensjonsmodell: Enkeltgruppeoppdrag
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: HER2 Vaccine Arm

MVF-HER2 266-296 and MVF HER2 597-626 peptide vaccines are combined in 1.5 mg doses of each peptide into a 3.0 mg total dose. This is administered intramuscularly in the gluteus maximus once every 21 days for three doses, in alternating sides (i.e. left->right->left), with a booster administered at 6 months.

MVF-HER2 266-296 and MVF HER2 597-626 peptide vaccines

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Evaluation of safety and toxicity at regular intervals by NCI common toxicity criteria 5.0
Tidsramme: through completion of 3 vaccine series (i.e. up to day 64 post final vaccine injection)

Number of adverse events as assessed by the NCI CTCAE v. 5.0

through completion of 3 vaccine series (i.e. up to day 64 post final vaccine injection)
Immune Response
Tidsramme: through completion of 3 vaccine series (i.e. up to day 64 post final vaccine injection)

Humoral immune response will be measured by ELISA quantification of IgM and IgG antibodies to HER2 (597-626) and HER2 (266-296).

through completion of 3 vaccine series (i.e. up to day 64 post final vaccine injection)

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Hovedetterforsker: Pravin Kaumaya, PhD, Indiana University

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Antatt)

1. januar 2027

Primær fullføring (Antatt)

1. desember 2029

Studiet fullført (Antatt)

1. mars 2030

Datoer for studieregistrering

Først innsendt

22. april 2025

Først innsendt som oppfylte QC-kriteriene

22. april 2025

Først lagt ut (Faktiske)

29. april 2025

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

5. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

3. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

UBESLUTTE

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere